Communiqués Gene Biotherapeutics, Inc.

Actions

CRXM

US8767671048

Marché Fermé - OTC Markets Autres places de cotation 21:37:54 15/07/2024			Varia. 5j.	Varia. 1 janv.
0,000001 ^USD	0,00 %		0,00 %	0,00 %

2022	Gene Biotherapeutics, Inc. L'auditeur soulève un doute sur la pérennité de l'entreprise	CI
2021	Gene Biotherapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2020	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

GENE BIOTHERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	14/04/22	AQ
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	30/03/22	AQ
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	27/10/21	AQ
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	03/09/21	AQ
GENE BIOTHERAPEUTICS : Changes in Registrant's Certifying Accountant (form 8-K/A)	09/08/21	AQ
GENE BIOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	05/08/21	AQ
GENE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	28/07/21	AQ
GENE BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	26/04/21	AQ
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23/04/21	AQ
GENE BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	28/05/20	AQ
Cardium Therapeutics : Angionetics To Present At Marcum 2017 MicroCap conference In New York City	12/06/17	PU
Cardium Therapeutics : Angionetics To Present At Globalization Of Research And Industrialization Of Bio-Medicine Summit 2017 In Shenzhen, China	05/06/17	PU
Cardium Therapeutics : Angionetics To Present At The Biotechnology Industry Organization CEO & Investor Conference At The Waldorf Astoria New York City	09/02/17	PU
Cardium Therapeutics : FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease	07/02/17	PU
Cardium Therapeutics : Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease	09/01/17	PU
Cardium Therapeutics : Angionetics' Generx® Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease	12/09/16	PU
Cardium Therapeutics : Angionetics & A Huapont Life Sciences Affiliate Enter Agreement To Commercialize Generx® Angiogenic Gene Therapy Product Candidate For Ischemic Heart Disease In China	11/07/16	PU
Cardium Therapeutics : Angionetics & A Huapont Life Sciences (China) Affiliate Enter Into Equity Financing Agreement For Phase 3 Clinical Development Of Generx Gene Therapy For Ischemic Heart Disease	11/07/16	PU
Cardium Therapeutics : Angionetics To Present At 2015 LD Micro Invitational Investor Conference On Business And Generx® Phase 3 Clinical Development Activities	26/05/15	PU
Cardium Therapeutics : Angionetics Presents at the 2015 American Society of Gene & Cell Therapy Conference On Generx® Angiogenic Phase 3 Gene Therapy Program	15/05/15	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Gene Biotherapeutics, Inc.

Actions

CRXM

US8767671048

Communiqués

Filtres